|
30 Jan 2012 |
VGX-100 Identified as Potential New Therapy for Improving Corneal Graft Survival
|
|
30 Jan 2012 |
biOasis Advances its Herceptin(R) BT2111 Program
|
|
29 Jan 2012 |
Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source
|
|
29 Jan 2012 |
Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS in Front-line Mature T-Cell Lymphomas
|
|
29 Jan 2012 |
Seattle Genetics Announces Data from ADCETRIS in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
|
|
26 Jan 2012 |
ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis
|
|
25 Jan 2012 |
Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN
|
|
24 Jan 2012 |
Baxter to Initiate Second Phase III Trial Studying GAMMAGARD LIQUID (IGIV) for the Treatment of Alzheimer’s Disease
|
|
23 Jan 2012 |
ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in “CANCER”, the Journal of the American Cancer Society
|
|
21 Jan 2012 |
Remicade® (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
|
|
21 Jan 2012 |
Immunomedics Reports Final Results From Phase Ib/II Study of Yttrium-90-Labeled Clivatuzumab Tetraxetan and Gemcitabine in Advanced Pancreatic Cancer
|
|
21 Jan 2012 |
FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor
|
|
18 Jan 2012 |
InflaRx Announces Successful Conduct of Its Clinical Phase I Trial with IFX-1, a New Monoclonal Antibody Inhibiting Complement Driven Inflammation
|
|
13 Jan 2012 |
Seattle Genetics Announces Updates to ADCETRIS™ Prescribing Information
|
|
13 Jan 2012 |
Genentech Announces First Milestone Payment to Device-Maker ForSight VISION4, Inc. in Development of Sustained Delivery Lucentis
|
|
12 Jan 2012 |
Three Adimab Antibodies Enter Human Clinical Trials
|
|
09 Jan 2012 |
Biocon Announces Positive Efficacy Data with its Novel Monoclonal Antibody Itolizumab in a Pivotal Psoriasis Study
|
|
09 Jan 2012 |
Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
|
|
09 Jan 2012 |
Thallion and LFB Complete Patient Enrollment of Phase II SHIGATEC Trial
|
|
09 Jan 2012 |
Baxter Submits Application for FDA Approval of GAMMAGARD LIQUID to Treat Multifocal Motor Neuropathy, a Degenerative Neurological Disorder
|
|
02 Jan 2012 |
Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott
|
|
30 Dec 2011 |
Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer
|
|
29 Dec 2011 |
Peregrine Provides Update on HCV Clinical Program
|
|
28 Dec 2011 |
Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia
|
|
21 Dec 2011 |
XOMA Initiates Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris
|
